Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metrizoic Acid SCHEMBL29570734 | 0.98 | LMNA (0.52) | LMNASMN1; SMN2TSHRMAPK1 | |
| Metrizoic Acid SCHEMBL37641 | 0.98 | LMNA (0.52) | LMNASMN1; SMN2TSHRMAPK1 | |
| Metrizoic Acid SCHEMBL1236887 | 0.97 | LMNA (0.51) | LMNASMN1; SMN2TSHRMAPK1 | |
| Metrizoic Acid SCHEMBL10324624 | 0.90 | LMNA (0.61) | LMNASMN1; SMN2 | |
| SCHEMBL11589910 | 0.87 | LMNA (0.44) | LMNASMN1; SMN2 | |
| SCHEMBL11630055 | 0.87 | LMNA (0.42) | LMNASMN1; SMN2TSHRMAPK1 | |
| SCHEMBL8492195 | 0.85 | LMNA (0.53) | LMNASMN1; SMN2 | |
| SCHEMBL11634960 | 0.84 | LMNA (0.43) | LMNASMN1; SMN2TSHRMAPK1 | |
| SCHEMBL11586365 | 0.84 | LMNA (0.43) | LMNASMN1; SMN2TSHRMAPK1 | |
| Metrizoic Acid SCHEMBL8060104 | 0.84 | LMNA (0.64) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| US-10722562-B2 | Combinatorial analysis and repair | IMMUDEX APS (DK) | 2020-07-28 | — | — | US | disclosed |
| US-20180015172-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| US-20170216314-A1 | TOPICAL FORMULATIONS | NUVO RESEARCH INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9642912-B2 | Topical formulations for treating skin conditions | CRESCITA THERAPEUTICS INC. (CA) | 2017-05-09 | — | — | US | disclosed |
| WO-2016118787-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-9308181-B2 | Topical formulations, systems and methods | NUVO RESEARCH INC. (CA) | 2016-04-12 | — | — | US | disclosed |
| US-20150297723-A1 | TOPICAL FORMULATIONS FOR TREATING SKIN CONDITIONS | NUVO RESEARCH INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20130337031-A1 | TOPICAL FORMULATIONS, SYSTEMS AND METHODS | NUVO RESEARCH INC. (CA) | 2013-12-19 | — | — | US | disclosed |
| US-20130079404-A1 | TOPICAL FORMULATION | NUVO RESEARCH INC. (CA) | 2013-03-28 | — | — | US | disclosed |
| US-8343962-B2 | Topical formulation | NUVO RESEARCH INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| US-20110212090-A1 | Combinatorial Analysis and Repair | DAKO DENMARK A/S | 2011-09-01 | — | — | US | disclosed |
| US-20110028460-A1 | TOPICAL FORMULATION | FQUBED, INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2010009735-A2 | COMBINATORIAL ANALYSIS AND REPAIR | DAKO DENMARK A/S (DK) | 2010-01-28 | — | — | WO | disclosed |
| US-20080319092-A1 | Transdermal Drug Delivery Formulation | NUVO RESEARCH INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | disclosed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130337031-A1 | TOPICAL FORMULATIONS, SYSTEMS AND METHODS | SMURF1, SMURF2, SMS | LMNA 2380/4885SMN1; SMN2 874/4885TSHR 4577/4885 |
| US-20110028460-A1 | TOPICAL FORMULATION | SPTLC1, SPTSSB, SPTLC3 | LMNA 2597/4885SMN1; SMN2 1668/4885TSHR 4821/4885 |
| US-20150297723-A1 | TOPICAL FORMULATIONS FOR TREATING SKIN CONDITIONS | SMURF1, SGMS1, SMURF2 | LMNA 2514/4885SMN1; SMN2 1196/4885TSHR 4834/4885 |
| US-20170216314-A1 | TOPICAL FORMULATIONS | SMURF1, SGMS1, SPTLC1 | LMNA 2342/4885SMN1; SMN2 981/4885TSHR 4877/4885 |
| US-20130079404-A1 | TOPICAL FORMULATION | SPTLC1, SPTLC3, SARAF | LMNA 792/4885SMN1; SMN2 963/4885TSHR 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.